{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:18:32Z","timestamp":1773796712773,"version":"3.50.1"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ctrv.2016.11.015","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T17:18:27Z","timestamp":1482427107000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Rituximab: 13 open questions after 20years of clinical use"],"prefix":"10.1016","volume":"53","author":[{"given":"Francesca","family":"Pavanello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ctrv.2016.11.015_b0015","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0025","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.015_b0030","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ctrv.2016.11.015_b0035","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.015_b0040","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.015_b0050","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.015_b0055","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00d74 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ctrv.2016.11.015_b0060","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin\u2019s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2016.11.015_b0065","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2016.11.015_b0070","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9759","key":"10.1016\/j.ctrv.2016.11.015_b0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0080","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2016.11.015_b0085","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0090","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom\u2019s macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1023\/A:1015463811683","article-title":"Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?","volume":"22","author":"Selenko","year":"2002","journal-title":"J Clin Immunol"},{"issue":"16","key":"10.1016\/j.ctrv.2016.11.015_b0100","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2016.11.015_b0105","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","article-title":"Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study","volume":"26","author":"Cartron","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0110","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3109\/10428194.2015.1014363","article-title":"Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas","volume":"56","author":"Kimby","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0115","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.015_b0120","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0125","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0130","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0135","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0140","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.015_b0145","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.015_b0150","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0155","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0165","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0170","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","article-title":"Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response","volume":"97","author":"Jager","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/10428194.2012.691482","article-title":"Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi\/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study","volume":"54","author":"Carella","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.ctrv.2016.11.015_b0180","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"Muller","year":"2012","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2016.11.015_b0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2016.11.015_b0190","first-page":"524","article-title":"Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE- R-CHOP-14 trial of the DSHNHL (EHA abstract S1347)","volume":"99","author":"Pfreundschuh","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.015_b0195","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"LBA8502","key":"10.1016\/j.ctrv.2016.11.015_b0200","article-title":"GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab refractory indolent non-Hodgkin lymphoma","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ctrv.2016.11.015_b0205","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.015_b0210","doi-asserted-by":"crossref","unstructured":"Vitolo U, et al. Obinutuzumab or Rituximab plus CHOP in patients with previously untreated Diffuse Large B-cell Lymphoma: final results from an open-label, randomized phase 3 study (GOYA). ASH, Abstract, 2016.","DOI":"10.1182\/blood.V128.22.470.470"},{"issue":"16","key":"10.1016\/j.ctrv.2016.11.015_b0215","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","article-title":"Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20","volume":"113","author":"Dayde","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0220","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","article-title":"Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL","volume":"25","author":"Murawski","year":"2014","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.ctrv.2016.11.015_b0225","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2013.54.6861","article-title":"Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group","volume":"32","author":"Pfreundschuh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0230","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0235","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-0609.2006.00713.x","article-title":"Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution","volume":"77","author":"Salar","year":"2006","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0240","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2006-11-059469","article-title":"Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2016.11.015_b0245","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1158\/1078-0432.CCR-08-1124","article-title":"A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function","volume":"14","author":"Siano","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0250","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0255","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/S2352-3026(16)00004-1","article-title":"Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial","volume":"3","author":"Assouline","year":"2016","journal-title":"Lancet Haematol"},{"issue":"6 Suppl. 12","key":"10.1016\/j.ctrv.2016.11.015_b0260","first-page":"30","article-title":"Chemotherapy sensitization by rituximab: experimental and clinical evidence","volume":"27","author":"Wilson","year":"2000","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0265","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0270","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.015_b0275","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1712.1712","article-title":"Addition of rituximab to salvage chemotherapy in aggressive CD20+ lymphoma prior to autologous stem cell transplant (ASCT): a cohort comparison from the NCIC CTG study LY.12","author":"Baetz","year":"2014","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.ctrv.2016.11.015_b0280","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1016\/j.ctrv.2016.11.015_b0285","article-title":"Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: results from the SEXIE-R-CHOP-14 trial of the DSHNHL","volume":"32","author":"Pfreundschuh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0290","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0295","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"15s","key":"10.1016\/j.ctrv.2016.11.015_b0300","article-title":"Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin\u2019s lymphoma (NHL)","volume":"28","author":"Pierz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0305","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2016.11.015_b0310","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0315","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.2011.04125.x","article-title":"Model-based design of rituximab dosage optimization in follicular non-Hodgkin\u2019s lymphoma","volume":"73","author":"Ternant","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.ctrv.2016.11.015_b0320","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/blood-2012-05-431825","article-title":"Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms","volume":"120","author":"Ghesquieres","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0325","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-15-1848","article-title":"Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma","volume":"22","author":"Kenkre","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2016.11.015_b0330","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2011-04-346411","article-title":"The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab","volume":"118","author":"Ahlgrimm","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0335","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2003-07-2548","article-title":"Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia","volume":"103","author":"Farag","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.015_b0340","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin\u2019s lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0345","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2141.2003.04737.x","article-title":"FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas","volume":"124","author":"Camilleri-Broet","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0355","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.13071","article-title":"Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35\/98)","volume":"168","author":"Lee","year":"2015","journal-title":"Br J Haematol"},{"issue":"29","key":"10.1016\/j.ctrv.2016.11.015_b0360","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.2013.53.4537","article-title":"Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab","volume":"32","author":"Bittenbring","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0365","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Davis","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0370","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.4049\/jimmunol.1103693","article-title":"Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients","volume":"188","author":"Beurskens","year":"2012","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0375","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","article-title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines","volume":"30","author":"Takei","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2016.11.015_b0380","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1182\/blood.V106.11.4819.4819","article-title":"Loss of expression of the pro-apoptotic Bcl-2 family proteins Bak and Bax in rituximab- and chemotherapy-resistant non-Hodgkin\u2019s lymphoma cells","volume":"106","author":"Olejniczak","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0385","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"Beum","year":"2006","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0390","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.4049\/jimmunol.177.10.7435","article-title":"Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia","volume":"177","author":"Williams","year":"2006","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0395","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2016.11.015_b0400","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0405","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0410","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","article-title":"B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis","volume":"106","author":"Dunleavy","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0415","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1012500524758","article-title":"Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin\u2019s lymphoma and corrected with IVIG","volume":"12","author":"Saikia","year":"2001","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0420","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0425","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: a systematic review","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.015_b0430","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.22666","article-title":"Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials","volume":"109","author":"Rafailidis","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0435","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(16)30045-X","article-title":"Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial","volume":"3","author":"Greil","year":"2016","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.015_b0440","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.24499","article-title":"Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy","volume":"91","author":"Barreto","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0445","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0450","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0455","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","article-title":"Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma","volume":"29","author":"Tarella","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0460","first-page":"1809","article-title":"Risk of second primary cancer in patients with B-cell non-Hodgkin lymphoma receiving rituximab-containing chemotherapy: a nationwide population-based study","volume":"35","author":"Cho","year":"2015","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0465","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0470","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0475","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2012.47.6994","article-title":"Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management","volume":"32","author":"Burnette","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.015_b0480","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ctrv.2016.11.015_b0485","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0490","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2014.57.6801","article-title":"Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)","volume":"33","author":"Wagner","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.015_b0495","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","author":"Williams","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0500","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3324\/haematol.2015.125344","article-title":"Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"Jaeger","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0505","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3109\/10428194.2013.871280","article-title":"Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma","volume":"55","author":"Sanchez-Gonzalez","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.ctrv.2016.11.015_b0510","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.015_b0515","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Bouabdallah K, Gyan E, Damaj G, et al. Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the Phase III Prospective Lyma Trial, a Lysa Study Blood (ASH Annual Meeting Abstracts); 2014. p. 146.","DOI":"10.1182\/blood.V124.21.146.146"},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.015_b0520","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"26","author":"Graf","year":"2015","journal-title":"Ann Oncol"},{"issue":"9383","key":"10.1016\/j.ctrv.2016.11.015_b0525","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.015_b0530","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ctrv.2016.11.015_b0535","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-Celigny","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0540","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0545","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjh.13895","article-title":"Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era","volume":"172","author":"Nastoupil","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.015_b0550","first-page":"CD003805","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma","volume":"4","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.015_b0555","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.ctrv.2016.11.015_b0560","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2016.11.015_b0565","first-page":"509","article-title":"Updated 6 years follow-up of the PRIMA study confirms the benefit of 2-years rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Salles","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.015_b0570","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.015_b0575","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.015_b0580","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ctrv.2016.11.015_b0585","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0590","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2016.11.015_b0595","unstructured":"Gyan E, Chinot O, et al. Addition of rituximab to the treatment of newly diagnosed primary CNS lymphoma is associated with improved outcome: a French LOC network study. Hematol Oncol 2015; 33: 216\u20137."},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.015_b0600","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cncr.29023","article-title":"Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0605","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0610","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2012","article-title":"Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without rituximab","volume":"31","author":"Papageorgiou","year":"2013","journal-title":"Hematol Oncol"},{"issue":"18s","key":"10.1016\/j.ctrv.2016.11.015_b0615","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","volume":"25","author":"Villa","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2016.11.015_b0620","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.015_b0625","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14712598.2012.758710","article-title":"Biosimilar monoclonal antibodies: a science-based regulatory challenge","volume":"13","author":"Declerck","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0630","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/0971-5851.125248","article-title":"Comparison of the efficacy and safety of Rituximab (Mabthera) and its biosimilar (Reditux) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis","volume":"34","author":"Roy","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0635","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/14737140.2015.1028919","article-title":"Biosimilar monoclonal antibodies in lymphoma: a critical appraisal","volume":"15","author":"Rioufol","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.015_b0640","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2010-07-298356","article-title":"The future of anti-CD20 monoclonal antibodies: are we making progress?","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.015_b0645","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.015_b0650","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0655","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Barth","year":"2012","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.ctrv.2016.11.015_b0660","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-0056","article-title":"Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma","volume":"21","author":"Barth","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.015_b0665","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V124.21.630.630","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd Study (OMB110928)","volume":"124","author":"van Imhoff","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2016.11.015_b0670","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2016.11.015_b0675","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.015_b0680","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.ctrv.2016.11.015_b0685","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.015_b0690","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Morschhauser","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.015_b0695","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-11-0850","article-title":"Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma","volume":"18","author":"Forero-Torres","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.015_b0700","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clim.2014.06.005","article-title":"A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed\/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics","volume":"154","author":"Casulo","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ctrv.2016.11.015_b0705","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8551","article-title":"Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab","volume":"31","author":"Tobinai","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T16:09:20Z","timestamp":1658246960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216301402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":141,"alternative-id":["S0305737216301402"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.015","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab: 13 open questions after 20years of clinical use","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}